SEMA3D: A Potential Drug Target and Biomarker for ALS (G223117)

Target Name: SEMA3D

NCBI ID: G223117

SEMA3D

SEMA3D: A Potential Drug Target and Biomarker for ALS

Semaphorin-3D (SEMA3D) is a protein that is expressed in the central nervous system (CNS) and has been shown to play a role in the development and progression of amyotrophic lateral sclerosis (ALS). ALS is a progressive neurodegenerative disorder that affects muscle strength and function, and is often treated with neuroimaging agents that can slow the progression of the disease.

SEMA3D is a transmembrane protein that is expressed in the CNS, including the brain, spinal cord, and peripheral nerves. It is a member of the semaphorin family of proteins, which are known for their role in the development and maintenance of the nervous system. Semaphorins are involved in a variety of physiological processes in the CNS, including the regulation of cell survival, the formation of neural circuits, and the modulation of pain perception.

SEMA3D has been shown to be involved in the development and progression of ALS by several different mechanisms. One of the ways that SEMA3D contributes to the development of ALS is by promoting the survival of motor neurons. Studies have shown that SEMA3D can interact with dopamine, a neurotransmitter that is involved in motor function, and that this interaction may contribute to the neurotoxicity of ALS.

Another way that SEMA3D contributes to the development of ALS is by increasing the formation of glial cells, which are support cells for motor neurons. Glial cells are responsible for maintaining the integrity of motor neurons and are thought to be a target for neurotoxins that can cause ALS. SEMA3D has been shown to interact with glial cells and to contribute to the neurotoxicity of ALS.

In addition to its role in promoting the survival of motor neurons and increasing the formation of glial cells, SEMA3D is also thought to be involved in the regulation of inflammation in the CNS. Studies have shown that SEMA3D can modulate the expression of genes involved in inflammation, including those that are involved in the development of neurodegenerative diseases.

SEMA3D is also a potential biomarker for ALS, as its levels have been shown to be decreased in the brains of people with ALS. This suggests that SEMA3D may be a useful target for diagnostic tests and therapies for ALS. Additionally, because SEMA3D is involved in a variety of physiological processes in the CNS, it may also be a useful target for other neurological disorders.

In conclusion, SEMA3D is a protein that is involved in the development and progression of ALS. Its role in this process is likely due to its interactions with dopamine, glial cells, and other cells in the CNS. SEMA3D is also a potential biomarker for ALS and may be a useful target for diagnostic tests and therapies for this disease. Further research is needed to fully understand the role of SEMA3D in ALS and to develop effective treatments.

Protein Name: Semaphorin 3D

Functions: Induces the collapse and paralysis of neuronal growth cones. Could potentially act as repulsive cues toward specific neuronal populations. Binds to neuropilin (By similarity)

The "SEMA3D Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SEMA3D comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets